Valuation: Design Therapeutics, Inc.

Market Cap 953M 817M 764M 699M 1.32B 91.26B 1.33B 9.04B 3.52B 45.83B 3.58B 3.5B 152B P/E 2026 *
-11.1x
P/E 2027 * -9.51x
Enterprise Value 977M 837M 783M 716M 1.35B 93.54B 1.37B 9.27B 3.6B 46.97B 3.67B 3.59B 155B EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
68.13%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Design Therapeutics, Inc.

1 day+2.76%
1 week+2.88%
Current month+28.98%
1 month+32.24%
3 months+37.81%
6 months+43.21%
Current year+67.48%
1 week 14.64
Extreme 14.64
16.12
1 month 11.45
Extreme 11.45
16.12
Current year 8.23
Extreme 8.23
17.25
1 year 4.92
Extreme 4.92
17.25
3 years 1.96
Extreme 1.96
17.25
5 years 1.94
Extreme 1.94
26.3
10 years 1.94
Extreme 1.94
50.5
Manager TitleAgeSince
Chief Executive Officer 56 2023-08-24
Chief Tech/Sci/R&D Officer 60 2025-04-16
Chief Tech/Sci/R&D Officer - 2025-01-31
Director TitleAgeSince
Chairman 56 2017-12-17
Director/Board Member 71 2019-06-30
Director/Board Member 49 2020-01-31
Date Insider Type Main position Quantity % Market Cap.
1/2/26 Free

Chief Executive Officer

750,000 1.3166%
1/2/26 Free

Director

45,000 0.0790%
1/2/26 Free

Controller/Auditor

150,000 0.2633%
Change 5-day change 1-year change 3-year change Capi.($)
+2.72%+2.88%+202.12%+655.29% 953M
+1.02%+4.95%+3.67%+25.46% 51.21B
+0.44%-1.56%+496.13%+541.64% 45.35B
-0.38%+7.83%+37.66%+18.18% 42.84B
+1.87%+2.71%+22.85%+91.10% 42.29B
-2.27%-5.67%+14.55%+50.34% 32.15B
-1.16%+3.34%+30.68%+134.79% 17.31B
+0.21%+1.53% - - 16.55B
+1.12%+6.35%+11.00%+32.62% 14.84B
-0.06%+6.97%+81.99%+49.04% 14.25B
Average +0.38%+2.84%+100.07%+177.61% 27.77B
Weighted average by Cap. +0.28%+2.89%+106.39%+138.81%

Financials

2026 *2027 *
Net sales - -
Net income -86.04M -73.74M -68.98M -63.07M -119M -8.24B -120M -816M -317M -4.14B -323M -316M -13.69B -115M -98.56M -92.2M -84.29M -159M -11.01B -161M -1.09B -424M -5.53B -432M -422M -18.29B
Net Debt 23.81M 20.41M 19.09M 17.45M 32.94M 2.28B 33.29M 226M 87.84M 1.14B 89.41M 87.47M 3.79B -295M -253M -237M -216M -408M -28.26B -413M -2.8B -1.09B -14.19B -1.11B -1.08B -46.95B
Logo Design Therapeutics, Inc.
Design Therapeutics, Inc. is a biotechnology company. It is engaged in the research and development of GeneTACT molecules, which are small-molecule gene targeted chimera therapeutic candidates designed to be disease-modifying by addressing the underlying cause of diseases caused by inherited nucleotide repeat expansion mutations. Its Friedreich ataxia (FA) program is focused on the development of a disease-modifying treatment. Its DT-216 is developed to overcome the FXN transcription impairment that causes FA. DT-216 is in Phase I clinical trial. It is also engaged in developing DT-216 to enable higher exposure and chronic administration for treatment of FA, known as DT-216P2, which uses the same drug substance, DT-216. Its FECD program is focused on the development of a potentially disease-modifying medical treatment for FECD, DT-168, which is in Phase I clinical trial. Its Huntington's Disease program is focused on the development of a potentially disease-modifying treatment for HD.
Employees
55
Date Price Change Volume
26-08-25 US$15.69 +3.02% 289,462
26-08-24 US$15.23 +1.60% 408,654
26-08-21 US$14.99 -3.66% 552,135
26-08-20 US$15.56 -2.38% 511,045
26-08-19 US$15.94 +4.39% 706,353
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
7
Last Close Price
15.23USD
Average target price
21.00USD
Spread / Average Target
+37.89%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. DSGN Stock